Fibrocell Science (FCSC) Post Smaller Q2 Loss

Fibrocell Science (NASDAQ: FCSC) reported Q3 EPS of ($0.07), $0.09 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $49 thousand versus the consensus estimate of $60 thousand.

As of September 30, 2015, the Company had cash and cash equivalents of $36.9 million.

“The field of gene therapy is rapidly evolving, and we are uniquely positioned as the only company developing personalized cell and gene therapies to treat rare diseases of the skin and connective tissue,” said David Pernock, Chairman and Chief Executive Officer. “We are working tirelessly to complete the steps to advance FCX-007 — our lead gene-therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) — into human clinical trials. RDEB is a devastating disease with currently no approved treatments, so to successfully develop FCX-007 and bring it to market could be transformational for patients living with RDEB, as well as their families.”

Mr. Pernock continued, “Our other programs, azficel-T for the treatment of chronic dysphonia, and FCX-013 for the treatment of linear scleroderma, continue to progress well. We expect to report Phase II data for chronic dysphonia in the second quarter of 2016, and we are on track to complete our proof-of-concept animal study for FCX-013 in the first half of next year.”

For earnings history and earnings-related data on Fibrocell Science (FCSC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• SanDisk upgraded at JPMorgan after investor day; shares climb